Literature DB >> 29611497

Validity of Time to Sputum Culture Conversion to Predict Cure in Patients with Multidrug-Resistant Tuberculosis: A Retrospective Single-Center Study.

Arshad Javaid1,2, Nafees Ahmad3, Afsar Khan Afridi2, Anila Basit4, Amer Hayat Khan5, Izaz Ahmad6, Muhammad Atif7.   

Abstract

To evaluate the predictive value of time to sputum culture conversion (SCC) in predicting cure and factors associated with time to SCC and cure in multidrug-resistant tuberculosis (MDR-TB) patients, a retrospective study was conducted at programmatic management unit of drug resistant tuberculosis (TB), Peshawar. A total of 428 pulmonary MDR-TB patients enrolled at the study site from January 1, 2012 to August 31, 2014 were followed until treatment outcome was recorded. Survival analysis using Cox proportional hazards model and multivariate binary logistic regression were, respectively, used to identify factors associated with time to SCC and cure. A P value < 0.05 was considered statistically significant. Overall, 90.9% patients achieved SCC, and 76.9% were cured. Previous use of second-line drugs (SLDs) (hazard ratio [HR] = 0.637; 95% confidence interval [CI] = 0.429-0.947), ofloxacin resistance (HR = 0.656; 95% CI = 0.522-0.825) and lung cavitation (HR = 0.744; 95% CI = 0.595-0.931) were significantly associated with time to SCC. In predicting cure, sensitivities of SCC at 2, 4, and 6 months were 64.1% (95% CI = 58.69-69.32), 93.0% (95% CI = 89.69-95.52), and 97.6% (95% CI = 95.27-98.94), respectively, whereas specificities were 67.7% (95% CI = 57.53-76.73), 51.5% (95% CI = 41.25-61.68), and 44.4% (95% CI = 34.45-54.78), respectively. Furthermore, patients' age of 41-60 (odds ratio [OR] = 0.202; 95% CI = 0.067-0.605) and > 60 years (OR = 0.051; 95% CI = 0.011-0.224), body weight > 40 kg (OR = 2.950; 95% CI = 1.462-5.952), previous SLD use (OR = 0.277; 95% CI = 0.097-0.789), lung cavitation (OR = 0.196; 95% CI = 0.103-0.371) and ofloxacin resistance (OR = 0.386; 95% CI = 0.198-0.749) were significantly associated with cure. Association of SCC with cure was substantially stronger at 6 months (OR = 32.10; 95% CI = 14.34-71.85) than at 4 months (OR = 14.13; 95% CI = 7.92-25.21). However in predicting treatment outcomes, the combined sensitivity and specificity of SCC at 4 months was comparable to SCC at 6 months. Patients with risk factors for delayed SCC were also at high risk of unsuccessful outcomes.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29611497      PMCID: PMC6086179          DOI: 10.4269/ajtmh.17-0936

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  25 in total

1.  The treatment of multidrug-resistant tuberculosis in Turkey.

Authors:  K Tahaoğlu; T Törün; T Sevim; G Ataç; A Kir; L Karasulu; I Ozmen; N Kapakli
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

2.  Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country.

Authors:  Arshad Javaid; Nafees Ahmad; Amer Hayat Khan; Zubair Shaheen
Journal:  Eur Respir J       Date:  2017-01-03       Impact factor: 16.671

3.  Sputum conversion among patients with pulmonary tuberculosis: are there implications for removal of respiratory isolation?

Authors:  Jesús Fortún; Pilar Martín-Dávila; Auxiliadora Molina; Enrique Navas; José Manuel Hermida; Javier Cobo; Enrique Gómez-Mampaso; Santiago Moreno
Journal:  J Antimicrob Chemother       Date:  2007-04       Impact factor: 5.790

4.  Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases.

Authors:  G B Migliori; C Lange; R Centis; G Sotgiu; R Mütterlein; H Hoffmann; K Kliiman; G De Iaco; F N Lauria; M D Richardson; A Spanevello; D M Cirillo
Journal:  Eur Respir J       Date:  2008-06       Impact factor: 16.671

5.  Management and treatment outcomes of MDR-TB: results from a setting with high rates of drug resistance.

Authors:  N Ahmad; A Javaid; A Basit; A K Afridi; M A Khan; I Ahmad; S A S Sulaiman; A H Khan
Journal:  Int J Tuberc Lung Dis       Date:  2015-09       Impact factor: 2.373

6.  Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India.

Authors:  Pauline Joseph; Vijaya Bhaskara Rao Desai; Nalini Sunder Mohan; Jemima Sheila Fredrick; Rajeswari Ramachandran; Balambal Raman; Fraser Wares; Ranjani Ramachandran; Aleyamma Thomas
Journal:  Indian J Med Res       Date:  2011-05       Impact factor: 2.375

Review 7.  Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis.

Authors:  James C Johnston; Neal C Shahidi; Mohsen Sadatsafavi; J Mark Fitzgerald
Journal:  PLoS One       Date:  2009-09-09       Impact factor: 3.240

8.  Use of Xpert(®) MTB/RIF assay in the first national anti-tuberculosis drug resistance survey in Pakistan.

Authors:  S Tahseen; E Qadeer; F M Khanzada; A H Rizvi; A Dean; A Van Deun; M Zignol
Journal:  Int J Tuberc Lung Dis       Date:  2016-04       Impact factor: 2.373

9.  Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies.

Authors:  Ekaterina V Kurbatova; J Peter Cegielski; Christian Lienhardt; Rattanawadee Akksilp; Jaime Bayona; Mercedes C Becerra; Janice Caoili; Carmen Contreras; Tracy Dalton; Manfred Danilovits; Olga V Demikhova; Julia Ershova; Victoria M Gammino; Irina Gelmanova; Charles M Heilig; Ruwen Jou; Boris Kazennyy; Salmaan Keshavjee; Hee Jin Kim; Kai Kliiman; Charlotte Kvasnovsky; Vaira Leimane; Carole D Mitnick; Imelda Quelapio; Vija Riekstina; Sarah E Smith; Thelma Tupasi; Martie van der Walt; Irina A Vasilyeva; Laura E Via; Piret Viiklepp; Grigory Volchenkov; Allison Taylor Walker; Melanie Wolfgang; Martin Yagui; Matteo Zignol
Journal:  Lancet Respir Med       Date:  2015-02-26       Impact factor: 30.700

10.  Effects of Multidrug Resistant Tuberculosis Treatment on Patients' Health Related Quality of Life: Results from a Follow Up Study.

Authors:  Nafees Ahmad; Arshad Javaid; Syed Azhar Syed Sulaiman; Anila Basit; Afsar Khan Afridi; Ammar Ali Saleh Jaber; Amer Hayat Khan
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

View more
  10 in total

1.  Treatment outcomes and associated factors among patients with multidrug-resistant tuberculosis in Ashanti Region, Ghana: a retrospective, cross-sectional study.

Authors:  Victoria Panford; Emmanuel Kumah; Collins Kokuro; Prince Owusu Adoma; Michael Afari Baidoo; Adam Fusheini; Samuel Egyakwa Ankomah; Samuel Kofi Agyei; Peter Agyei-Baffour
Journal:  BMJ Open       Date:  2022-07-05       Impact factor: 3.006

2.  Strengthening the response to drug-resistant TB in Pakistan: a practice theory-informed approach.

Authors:  S Abbas; M Kermode; S Kane
Journal:  Public Health Action       Date:  2020-12-21

3.  Treatment Outcomes of Extensively Drug-Resistant Tuberculosis in Pakistan: A Countrywide Retrospective Record Review.

Authors:  Muhammad Abubakar; Nafees Ahmad; Abdul Ghafoor; Abdullah Latif; Izaz Ahmad; Muhammad Atif; Fahad Saleem; Shereen Khan; Amjad Khan; Amer Hayat Khan
Journal:  Front Pharmacol       Date:  2021-03-31       Impact factor: 5.810

4.  Treatment outcomes among childhood extensively drug-resistant tuberculosis patients in Pakistan.

Authors:  Muhammad Abubakar; Nafees Ahmad; Muhammad Atif; Amer Hayat Khan; Abdul Ghafoor
Journal:  ERJ Open Res       Date:  2022-02-21

5.  Prognostic accuracy of time to sputum culture conversion in predicting cure in extensively drug-resistant tuberculosis patients: a multicentre retrospective observational study.

Authors:  Muhammad Abubakar; Nafees Ahmad; Muhammad Atif; Izaz Ahmad; Abdul Wahid; Asad Khan; Fahad Saleem; Abdul Ghafoor
Journal:  BMC Infect Dis       Date:  2022-03-02       Impact factor: 3.090

6.  High rate of successful treatment outcomes among childhood rifampicin/multidrug-resistant tuberculosis in Pakistan: a multicentre retrospective observational analysis.

Authors:  Farah Naz; Nafees Ahmad; Abdul Wahid; Izaz Ahmad; Asad Khan; Muhammad Abubakar; Shabir Ahmed Khan; Amjad Khan; Abdullah Latif; Abdul Ghafoor
Journal:  BMC Infect Dis       Date:  2021-12-04       Impact factor: 3.090

7.  Comparative effectiveness of individualized longer and standardized shorter regimens in the treatment of multidrug resistant tuberculosis in a high burden country.

Authors:  Abdul Wahid; Abdul Ghafoor; Abdul Wali Khan; Yaser Mohammed Al-Worafi; Abdullah Latif; Nisar Ahmed Shahwani; Muhammad Atif; Fahad Saleem; Nafees Ahmad
Journal:  Front Pharmacol       Date:  2022-09-06       Impact factor: 5.988

Review 8.  Current research toward optimizing dosing of first-line antituberculosis treatment.

Authors:  Helen McIlleron; Maxwell T Chirehwa
Journal:  Expert Rev Anti Infect Ther       Date:  2018-12-12       Impact factor: 5.091

9.  Predicting the artificial immunity induced by RUTI® vaccine against tuberculosis using universal immune system simulator (UISS).

Authors:  Marzio Pennisi; Giulia Russo; Giuseppe Sgroi; Angela Bonaccorso; Giuseppe Alessandro Parasiliti Palumbo; Epifanio Fichera; Dipendra Kumar Mitra; Kenneth B Walker; Pere-Joan Cardona; Merce Amat; Marco Viceconti; Francesco Pappalardo
Journal:  BMC Bioinformatics       Date:  2019-12-10       Impact factor: 3.169

10.  Time to sputum culture conversion and its predictors among patients with multidrug-resistant tuberculosis in Hangzhou, China: A retrospective cohort study.

Authors:  Qingchun Li; Min Lu; Evelyn Hsieh; Limin Wu; Yifei Wu; Meng Wang; Le Wang; Gang Zhao; Li Xie; Han-Zhu Qian
Journal:  Medicine (Baltimore)       Date:  2020-12-11       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.